Ligilactobacillus salivarius is a probiotic bacteria species that has been found to live in the gastrointestinal tract and exert a range of therapeutic properties including suppression of pathogenic bacteria.[1]
| Ligilactobacillus | |
|---|---|
| Scientific classification | |
| Domain: | |
| Phylum: | |
| Class: | |
| Order: | |
| Family: | |
| Genus: | |
| Binomial name | |
| Ligilactobacillus salivarius (Rogosa et al. 1953) Zheng et al. 2020
| |
| Synonyms | |
| |
Therapeutic research
editIrritable bowel syndrome
editLigilactobacillus salivarius has been found to be of benefit in the alleviation of flatulence in individuals suffering from irritable bowel syndrome.[2]
Pancreatic necrosis
editPancreatic necrosis, if left untreated, has an almost 100 percent fatality rate due to bacterial translocation[further explanation needed]. Ligilactobacillus salivarius has been found to have a wide spectrum of coverage against pathogenic organisms that translocate from the gastrointestinal tract thereby demonstrating therapeutic benefit in the management of pancreatic necrosis. Research has shown that the addition of this species along with other probiotic species (specifically Bifidobacterium bifidum, Bifidobacterium infantis, Lactobacillus acidophilus, Lacticaseibacillus casei, and Lactococcus lactis) suppressed pro-inflammatory cytokines and further suppressed bacterial overgrowth in the small intestine leading to a reduction in bacterial translocation.[3]
Atopic dermatitis
editSome studies have shown atopic dermatitis symptoms have been shown to be reversed in some children who given probiotics containing L. salivarius.[4][5][6]
Oral health
editL. salivarius has been shown in some studies to improve periodontal health by reducing bleeding on probing and inhibiting harmful bacteria. While some strains may increase the risk of dental caries, others can decrease levels of Streptococcus mutans and enhance salivary buffering capacity, which may create a protective effect against dental caries and tooth decay. Additionally, L. salivarius may help manage halitosis by reducing bacteria associated with bad breath.[5][6]
References
edit- ^ Neville, BA.; O'Toole, PW. (May 2010). "Probiotic properties of Lactobacillus salivarius and closely related Lactobacillus species". Future Microbiol. 5 (5): 759–74. doi:10.2217/fmb.10.35. PMID 20441548.
- ^ Ortiz-Lucas, M.; Tobías, A.; Saz, P.; Sebastián, JJ. (Jan 2013). "Effect of probiotic species on irritable bowel syndrome symptoms: A bring up to date meta-analysis". Rev Esp Enferm Dig. 105 (1): 19–36. doi:10.4321/s1130-01082013000100005. PMID 23548007.
- ^ Ridwan, BU.; Koning, CJ.; Besselink, MG.; Timmerman, HM.; Brouwer, EC.; Verhoef, J.; Gooszen, HG.; Akkermans, LM. (Jan 2008). "Antimicrobial activity of a multispecies probiotic (Ecologic 641) against pathogens isolated from infected pancreatic necrosis". Lett Appl Microbiol. 46 (1): 61–7. doi:10.1111/j.1472-765X.2007.02260.x. PMID 17944834.
- ^ Niccoli, A. A.; et al. (Nov–Dec 2014). "Preliminary Results on Clinical Effects of Probiotic Lactobacillius Salivarius LS01 in Children Affected by Atopic Dermatitis". Journal of Clinical Gastroenterology. 48 (48, supplement 1): S34–6. doi:10.1097/mcg.0000000000000233. PMID 25291124.
- ^ a b Chaves BD, Brashears MM, Nightingale KK (July 2017). "Applications and safety considerations of Lactobacillus salivarius as a probiotic in animal and human health". Journal of Applied Microbiology. 123 (1): 18–28. doi:10.1111/jam.13438. PMID 28256040.
- ^ a b Guerrero Sanchez M, Passot S, Campoy S, Olivares M, Fonseca F (January 2022). "Ligilactobacillus salivarius functionalities, applications, and manufacturing challenges". Applied Microbiology and Biotechnology. 106 (1): 57–80. doi:10.1007/s00253-021-11694-0. PMID 34889985.